Pharmacogenetics: Difference between revisions
| Line 6: | Line 6: | ||
Much of current clinical interest is at the level of pharmacogenetics, involving variation in genes involved in, [[drug metabolism]] with a particular emphasis on improving drug safety. The wider use of pharmacogenetic testing is viewed by many as an outstanding opportunity to improve prescribing safety and efficacy. Driving this trend are the 106,000 deaths and 2.2 Million serious events caused by adverse drug reactions in the US each year (Lazarou 1998). As such ADRs are responsible for 5-7% of hospital admissions in the US and Europe, lead to the withdrawal of 4% of new medicines and cost society an amount equal to the costs of drug treatment (Ingelman-Sundberg 2005). Comparisons of the list of drugs most commonly implicated in adverse drug reactions with the list of metabolizing enzymes with known [[Polymorphism (biology)|polymorphism]]s found that drugs commonly involved in adverse drug reactions were also those that were metabolized by enzymes with known polymorphisms (see Phillips, 2001). | Much of current clinical interest is at the level of pharmacogenetics, involving variation in genes involved in, [[drug metabolism]] with a particular emphasis on improving drug safety. The wider use of pharmacogenetic testing is viewed by many as an outstanding opportunity to improve prescribing safety and efficacy. Driving this trend are the 106,000 deaths and 2.2 Million serious events caused by adverse drug reactions in the US each year (Lazarou 1998). As such ADRs are responsible for 5-7% of hospital admissions in the US and Europe, lead to the withdrawal of 4% of new medicines and cost society an amount equal to the costs of drug treatment (Ingelman-Sundberg 2005). Comparisons of the list of drugs most commonly implicated in adverse drug reactions with the list of metabolizing enzymes with known [[Polymorphism (biology)|polymorphism]]s found that drugs commonly involved in adverse drug reactions were also those that were metabolized by enzymes with known polymorphisms (see Phillips, 2001). | ||
==History== | ==History== | ||
The first observations of genetic variation in drug response date from the 1950s, involving the muscle relaxant [[suxamethonium chloride]], and drugs metabolized by [[N-acetyltransferase]]. One in 3500 Caucasians has less efficient variant of the [[enzyme]] ([[butyrylcholinesterase]]) that [[metabolize]]s suxamethonium chloride <ref>Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006; 58:521-90</ref>. As a consequence, the drug’s effect is prolonged, with slower recovery from surgical paralysis. Variation in the [[N-acetyltransferase]] gene divides people into “slow acetylators” and “fast acetylators”, with very different [[Mean lifetime|half-lives]] and | The first observations of genetic variation in drug response date from the 1950s, involving the muscle relaxant [[suxamethonium chloride]], and drugs metabolized by [[N-acetyltransferase]]. One in 3500 Caucasians has less efficient variant of the [[enzyme]] ([[butyrylcholinesterase]]) that [[metabolize]]s suxamethonium chloride <ref>Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006; 58:521-90</ref>. As a consequence, the drug’s effect is prolonged, with slower recovery from surgical paralysis. Variation in the [[N-acetyltransferase]] gene divides people into “slow acetylators” and “fast acetylators”, with very different [[Mean lifetime|half-lives]] and blood concentrations of such important drugs as [[isoniazid]] (antituberculosis) and [[procainamide]] (antiarrhythmic). As part of the inborn system for clearing the body of [[xenobiotic]]s, the [[cytochrome P450 oxidase]]s (CYP450) are heavily involved in [[drug metabolism]], and genetic variations in CYP450s affect large populations. One member of the CYP450 superfamily, [[CYP2D6]], now has over 75 known allelic variations, some of which lead to no activity, and some to enhanced activity. An estimated 29% of people in parts of East Africa may have multiple copies of the gene, and will therefore not be adequately treated with standard doses of drugs such as the painkiller [[codeine]] (which is activated by the enzyme). | ||
==Thiopurines and TPMT (thiopurine methyl transferase)== | ==Thiopurines and TPMT (thiopurine methyl transferase)== | ||
Revision as of 13:14, 9 January 2009
|
WikiDoc Resources for Pharmacogenetics |
|
Articles |
|---|
|
Most recent articles on Pharmacogenetics Most cited articles on Pharmacogenetics |
|
Media |
|
Powerpoint slides on Pharmacogenetics |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Pharmacogenetics at Clinical Trials.gov Trial results on Pharmacogenetics Clinical Trials on Pharmacogenetics at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Pharmacogenetics NICE Guidance on Pharmacogenetics
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Pharmacogenetics Discussion groups on Pharmacogenetics Patient Handouts on Pharmacogenetics Directions to Hospitals Treating Pharmacogenetics Risk calculators and risk factors for Pharmacogenetics
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Pharmacogenetics |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
The terms pharmacogenomics and pharmacogenetics tend to be used interchangeably, and a precise, consensus definition of either remains elusive. Pharmacogenetics is generally regarded as the study or clinical testing of genetic variation that gives rise to differing response to drugs, while pharmacogenomics is the broader application of genomic technologies to new drug discovery and further characterization of older drugs. Pharmacogenetics considers one or at most a few genes of interest, while pharmacogenomics considers the entire genome.
Pharmacogenetics and adverse drug reactions
Much of current clinical interest is at the level of pharmacogenetics, involving variation in genes involved in, drug metabolism with a particular emphasis on improving drug safety. The wider use of pharmacogenetic testing is viewed by many as an outstanding opportunity to improve prescribing safety and efficacy. Driving this trend are the 106,000 deaths and 2.2 Million serious events caused by adverse drug reactions in the US each year (Lazarou 1998). As such ADRs are responsible for 5-7% of hospital admissions in the US and Europe, lead to the withdrawal of 4% of new medicines and cost society an amount equal to the costs of drug treatment (Ingelman-Sundberg 2005). Comparisons of the list of drugs most commonly implicated in adverse drug reactions with the list of metabolizing enzymes with known polymorphisms found that drugs commonly involved in adverse drug reactions were also those that were metabolized by enzymes with known polymorphisms (see Phillips, 2001).
History
The first observations of genetic variation in drug response date from the 1950s, involving the muscle relaxant suxamethonium chloride, and drugs metabolized by N-acetyltransferase. One in 3500 Caucasians has less efficient variant of the enzyme (butyrylcholinesterase) that metabolizes suxamethonium chloride [1]. As a consequence, the drug’s effect is prolonged, with slower recovery from surgical paralysis. Variation in the N-acetyltransferase gene divides people into “slow acetylators” and “fast acetylators”, with very different half-lives and blood concentrations of such important drugs as isoniazid (antituberculosis) and procainamide (antiarrhythmic). As part of the inborn system for clearing the body of xenobiotics, the cytochrome P450 oxidases (CYP450) are heavily involved in drug metabolism, and genetic variations in CYP450s affect large populations. One member of the CYP450 superfamily, CYP2D6, now has over 75 known allelic variations, some of which lead to no activity, and some to enhanced activity. An estimated 29% of people in parts of East Africa may have multiple copies of the gene, and will therefore not be adequately treated with standard doses of drugs such as the painkiller codeine (which is activated by the enzyme).
Thiopurines and TPMT (thiopurine methyl transferase)
One of the earliest tests for a genetic variation resulting in a clinically important consequence was on the enzyme thiopurine methyltransferase (TPMT). TPMT metabolizes 6-mercaptopurine and azathioprine, two thiopurine drugs used in a range of indications, from childhood leukemia to autoimmune diseases. In people with a deficiency in TPMT activity, thiopurine metabolism must proceed by other pathways, one of which leads to the active thiopurine metabolite that is toxic to the bone marrow at high concentrations. Deficiency of TPMT affects a small proportion of people, though seriously. One in 300 people have two variant alleles and lack TPMT activity; these people need only 6-10% of the standard dose of the drug, and, if treated with the full dose, are at risk of severe bone marrow suppression. For them, genotype predicts clinical outcome, a prerequisite for an effective pharmacogenetic test. In 85-90% of affected people, this deficiency results from one of three common variant alleles. Around 10% of people are heterozygous - they carry one variant allele - and produce a reduced quantity of functional enzyme. Overall, they are at greater risk of adverse effects, although as individuals their genotype is not necessarily predictive of their clinical outcome, which makes the interpretation of a clinical test difficult. Recent research suggests that patients who are heterozygous may have a better response to treatment, which raises whether people who have two wild-type alleles could tolerate a higher therapeutic dose. The US Food and Drug Administration (FDA) have recently deliberated the inclusion of a recommendation for testing for TPMT deficiency to the prescribing information for 6-mercaptopurine and azathioprine. Hitherto the information has carried the warning that inherited deficiency of the enzyme could increase the risk of severe bone marrow suppression. Now it will carry the recommendation that people who develop bone marrow suppression while receiving 6-mercaptopurine or azathioprine be tested for TPMT deficiency.
References
- Abbott A. With your genes? Take one of these, three times a day. Nature 2003;425:760-762.
- Evans WE and McLeod HL. Pharmacogenomics – Drug Disposition, Drug Targets, and Side Effects. New Engl J Med 2003;348:358-349.
- Ingelman-Sundberg M, Rodrquez-Antona C, Pharmacogenetics of drug-maetabolizing enzymes: implications for a safer and more effective drug therapy. Phil Trans R Soc B 360:1563-1570 2005
- Lazarou, J, Pomeranz BH, Corey PN, Incidence of Adverse Drug Reactions in Hospitalized Patients: A meta-analysis of prospective studies. JAMA 1998;279:1200-1205
- Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001;286:2270-2279.
- Weinshilboum R. Inheritance and Drug Response. New Engl J Med 2003; 348:529-537.
- ↑ Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006; 58:521-90
See also
External links
- Pharmacogenomics: Medicine and the new genetics from the Human Genome Project
- Pharmacogenomics in Drug Discovery and Development, a book on pharmacogenomics, diseases, personalized medicine, and therapeutics
- The Pharmacogenomics Journal
- PharmGKB The Pharmacogenetics and Pharmacogenomics Knowledge Base, a free online tool for Pharmacogenetics research
- The pharmacogenetics Wikibase
Template:Pharmacology Template:Genomics-footer Template:SIB